Personalized immune cells target Virus-Driven cancer in early trial
NCT ID NCT07162012
Summary
This early-phase study is testing a personalized cell therapy for patients with EBV-positive lymphoma that has returned or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack the Epstein-Barr virus (EBV) inside cancer cells, and then infuse them back. The main goals are to find a safe dose and see if this approach shows early signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.